Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial

Table 7 Heat map for stratifying cardiovascular risk according to glomerular filtration rate and albuminuria/creatinuria ratio in diabetic patients at 6-month assessment, n (%)

CKD classification				ACR
				A1 (normal or average increase, < 30 mg/g)	A2 (moderate increase, 30-299 mg/g)	A3 (severe increase, ≥ 300 mg/g)
GFR categories (mL/minute/1.73 m2)	G1	Normal or high	≥ 90	2 (0.6)1	4 (1.3)2	1 (0.3)3
	G2	Average decrease	60-89	11 (3.5)1	19 (6.1)2	5 (1.6)3
	G3	Average to moderate decrease	45-59	9 (2.9)2	74 (23.6)3	10 (3.2)3
	G4	Moderate to severe decrease	30-44	18 (5.7)3	62 (19.7)3	5 (1.6)3
	G5	Severe decrease	15-29	40 (12.7)3	38 (12.1)3	16 (5.1)3
	G6	Kidney failure	< 15	0 (0.0)3	0 (0.0)3	0 (0.0)3

¹Moderate risk.

²High risk.

³Vary high risk.

Severe target organ damage is defined as follows: (1) Estimated glomerular filtration rate < 45 mL/minute/1.73 m² independent of albuminuria; (2) Albuminuria/creatinuria ratio > 300mg/g: (A3) independent of estimated glomerular filtration rate; (3) Estimated glomerular filtration rate 45-59 mL/minute/1.73 m² with albuminuria/creatinuria ratio 30-300 mg/g (A2); and (4) Presence of microangiopathy in at least three locations [e.g., albuminuria (stage A2) retinopathy and neuropathy]. CKD: Chronic kidney disease; GFR: Glomerular filtration rate; ACR: Albuminuria/creatinuria ratio.